Invokana

Chemical Namecanagliflozin
Dosage FormTablets (oral; 100mg, 300mg)
Drug ClassInhibitors
SystemEndocrine
CompanyJanssen Pharmaceuticals, Inc.
Approval Year2013

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Last updated on 4/28/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Invokana (canagliflozin) Prescribing Information2013Janssen Pharmaceuticals, Inc., Titusville NJ
Document TitleYearSource
Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. 2021Current Diabetes Review
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systematic review and network meta-analysis. 2020Annals of Internal Medicine
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.2020Heart Failure Reviews
Cardiovascular outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and chronic kidney disease: An updated meta-analysis of randomized controlled trials. 2020Cardiology in Review
Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: A systematic review and meta-analysis.2020Medical Sciences
Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials. 2020Diabetes Research and Clinical Practice
Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: A systematic literature review and network meta-analysis.2019Diabetes Therapy
Peripheral artery disease and amputations with sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials .2019Diabetes Research and Clinical Practice
Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.2018Journal of Pharmacy and Pharmaceutical Sciences
Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials. 2018Diabetes Research and Clinical Practice
Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. 2018Current Medical Research and Opinion
Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis.2018Saudi Journal of Biological Sciences
SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.2017Diabetologia
Sodium‐glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta‐ analysis. 2017Diabetes Metabolism Research and Reviews
Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials.2017BMC Pharmacology and Toxicology
Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.2017Diabetes, Obesity and Metabolism
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. 2017Diabetes, Obesity and Metabolism
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.2016BMJ Open
Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 Diabetes: A systematic review and meta-analysis.2016PLoS One
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials. 2016Diabetes, Obesity and Metabolism
Efficacy and safety of canagliflozin in patients with type 2 diabetes; A meta-analysis of randomized controlled trials.2016Medicine
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.2016Diabetologia
Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials.2016Journal of Diabetes Investigation
Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. 2016International Journal of Cardiology